Dear Colleague:

This is an update on the new 2-dose human papillomavirus (HPV) vaccine series and on the supply of Pentacel® (DTap-IPV/Hib vaccine).

**HPV Vaccine**

As per our letter of October 28, 2016, HPV vaccine may be administered to adolescents 9-14 years of age on a 2-dose schedule, at 0 and 6-12 months (with a minimum interval between doses of 5 months). We want to clarify that *any* HPV vaccine product that was given counts toward either of the doses. Although all of the HPV vaccine available in the United States is the 9-valent (Gardasil 9®), in the past there have been the 2-valent HPV vaccine (Cervarix®) and the 4-valent HPV vaccine (Gardasil®) formulations. In addition, it is possible that your patients could have received either the bivalent or quadrivalent vaccine if vaccinated in another country. If either of those vaccines were administered at least five months apart to an adolescent 9-14 years of age as the first and/or second doses of HPV vaccine, then the series should be considered complete.

We also want to make you aware that the Citywide Immunization Registry (CIR) decision support now recognizes the 2-dose HPV vaccine series. Therefore, the recommendations you see in the Next Due of the CIR’s Immunization History page reflects the need for only two doses of HPV vaccine in the above-referenced situations.

**Pentacel**

Sanofi has communicated that the supply situation with Pentacel has resolved and that there are no longer any restrictions on the availability of this vaccine through the Vaccines for Children (VFC) program or private sector. Please note that you are expected to use VFC product (e.g., Pediarix® and Daptacel®) that you already have in stock before switching back to your previous pre-shortage Pentacel usage levels. Also note that the VFC Recommended Quantity by Dose on the CIR ordering screen may be low, since it is based on previous usage, and that you may order more than recommended quantity once your substitute product’s supply is exhausted.

For questions on HPV vaccine, Pentacel supply, or any other vaccine-related issue, please contact (347) 396-2400 or email nycimmunize@health.nyc.gov. Thank you for keeping NYC children safe from vaccine-preventable diseases.

Sincerely,

Jane R. Zucker, MD, MSc